Investor Presentation H1 2023

19 Investor presentation First six months of 2023 Financial outlook for 2023 Sales growth - at CER Expectations 10 August 2023 27% to 33% Expectations 4 May 2023 24% to 30% Sales growth - reported Operating profit growth - at CER Around 6 percentage points lower 31% to 37% Around 6 percentage points lower 28% to 34% Operating profit growth - reported Around 9 percentage points lower Around 9 percentage points lower Financial items (net) Effective tax rate Free cash flow Gain of around DKK 2.8 billion Gain of around DKK 3.0 billion 19% to 21% DKK 64 to 72 billion 19% to 21% DKK 66 to 74 billion Novo NordiskⓇ The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 7 August 2023 Note: Changes since last highlighted in bold CER: Constant exchange rates

View entire presentation